Compass Pathways (CMPS) announced it is entering into its seventh strategic collaboration, with Radial Health, a national network of interventional psychiatry practices. This collaboration will further help to inform the development of scalable delivery models for investigational COMP360 psilocybin treatment, if FDA approved. The agreement with Radial expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with mental health conditions receive their care in the United States.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Buy Rating for COMPASS Pathways: Anticipated Phase 3 Data to Shape COMP360’s Future in Treatment-Resistant Depression Market
- Psychedelic: Atai Beckley granted U.S. patent for EMP-01
- Compass Pathways upgraded to Outperform at Oppenheimer on COMP360 potential
- Compass Pathways upgraded to Outperform from Perform at Oppenheimer
- Buy Rating for COMPASS Pathways: Accelerated Clinical Development and Strategic Position in Mental Health Sector